



NATCO PHARMA LIMITED

Statement of stand-alone Financial Results for the quarter ended 30th June 2015

Rs. lakhs

PART I : STATEMENT OF STAND-ALONE FINANCIAL RESULTS PARTICULARS	THREE MONTHS ENDED (REVIEWED/UNAUDITED)			YEAR ENDED (AUDITED)
	30 June 2015	31 March 2015	30 June 2014	31 March 2015
01. Gross Sales/Income from Operations	19,699	17,444	17,074	69,164
Less: Excise Duty	530	426	466	1,143
Less: Sales Tax	552	456	408	1,571
<b>Net Sales/Income from Operations</b>	<b>18,617</b>	<b>16,562</b>	<b>16,200</b>	<b>66,450</b>
02. Other Operating Income	788	1,023	1,948	5,107
<b>03. TOTAL INCOME FROM OPERATIONS</b>	<b>19,405</b>	<b>17,585</b>	<b>18,148</b>	<b>71,557</b>
<b>04. EXPENDITURE</b>				
a) Cost of materials consumed	6,181	5,265	3,892	17,858
b) Purchases of stock-in-trade	37	88	-	88
c) Changes in inventories of finished goods, work-in progress and stock-in-trade	(1,025)	(1,880)	477	(876)
d) Employee benefits expense	3,464	3,202	2,715	11,619
e) Depreciation and amortization expense	1,120	1,129	1,019	4,246
f) Other Expenses	4,693	4,985	5,008	20,010
<b>TOTAL EXPENSES</b>	<b>14,470</b>	<b>12,789</b>	<b>13,111</b>	<b>52,945</b>
<b>05. Profit/(Loss) from Operations before other income, finance costs and exceptional items</b>	<b>4,935</b>	<b>4,796</b>	<b>5,037</b>	<b>18,612</b>
06. Other Income	283	255	88	1,355
<b>07. Profit/(Loss) from ordinary activities before finance Cost and exceptional items</b>	<b>5,218</b>	<b>5,051</b>	<b>5,125</b>	<b>19,967</b>
08. Finance costs	777	867	636	3,013
<b>09. Profit/(Loss) from ordinary activities after finance Costs but before exceptional items</b>	<b>4,441</b>	<b>4,184</b>	<b>4,489</b>	<b>16,954</b>
10. Exceptional Item	-	-	-	1,513
<b>11. Profit/(Loss) from ordinary activities before tax</b>	<b>4,441</b>	<b>4,184</b>	<b>4,489</b>	<b>15,441</b>
12. Current Tax expense	948	777	941	3,252
13. Deferred Tax expense /(reversal)	86	(3,103)	(93)	(3,103)
<b>14. Net Profit/Loss(-) from ordinary activities after tax</b>	<b>3,407</b>	<b>6,510</b>	<b>3,641</b>	<b>15,292</b>
15. Extraordinary items (net of tax expenses)	-	-	-	-
<b>16. Net Profit/(Loss) for the period</b>	<b>3,407</b>	<b>6,510</b>	<b>3,641</b>	<b>15,292</b>
17. Paid-up Equity Share Capital (each share of Rs.10/-face value)	3,323	3,323	3,307	3,323
18. Reserves excluding revaluation reserves as per Balance Sheet of previous accounting year	-	-	-	84,576
<b>19. Earnings per share</b>				
Basic and diluted EPS before and after extraordinary item (Rs.) – non-annualized	10.25	19.63	11.01	46.17
	10.25	19.63	11.01	46.17
<b>PART II : SELECT INFORMATION</b>				
20. Public Share holding :				
a) Number of Shares	1,53,68,985	1,53,73,985	1,53,73,943	1,53,73,985
b) Percentage of Share holding	46.24	46.26	46.48	46.26
21. Promoters and Promoter Group Shareholding				
a) Pledged/Encumbered – No.of shares	-	-	-	-
b) Non-encumbered–No.of shares	1,78,65,864	1,78,60,864	1,76,99,131	1,78,60,864
Percentage (as a % of the total share holding of promoter and promoter group)	100.00	100.00	100.00	100.00
Percentage (as a % of the total share capital of the company)	53.76	53.74	53.52	53.74

Dated at Hyderabad, this, the 12th day of August, 2015.

for and on behalf of the Board of Directors,

NATCO Pharma Limited

*R. Nannapaneni*  
**Kajeev Nannapaneni**  
 Vice Chairman & CEO

Status of Investor Complaints as at 30th June, 2015	
Pending as on 01-04-2015	-
Received during the quarter	115
Resolved during the quarter	115
Pending as on 30-06-2015	-



**Statement of consolidated Financial Results for the quarter ended 30th June 2015**

Rs. lakhs

<b>PART I : STATEMENT OF CONSOLIDATED RESULTS</b>				
PARTICULARS	THREE MONTHS ENDED (UNREVIEWED/UNAUDITED)			YEAR ENDED (AUDITED)
	30 June 2015	31 March 2015	30 June 2014	31 March 2015
01. Gross Sales/Income from Operations	22,745	19,979	19,922	80,306
Less: Excise Duty	531	466	466	1,295
Less: Sales Tax	645	456	408	1,591
<b>Net Sales/Income from Operations</b>	<b>21,569</b>	<b>19,057</b>	<b>19,048</b>	<b>77,420</b>
02. Other Operating Income	802	1,023	1,948	5,107
<b>03. TOTAL INCOME FROM OPERATIONS</b>	<b>22,371</b>	<b>20,080</b>	<b>20,996</b>	<b>82,527</b>
<b>04. EXPENDITURE</b>				
a) Cost of materials consumed	5,744	6,872	6,088	16,726
b) Purchases of stock-in-trade	2,388	-	-	8,428
c) Changes in inventories of finished goods, work-in progress and stock-in-trade	(1,148)	(1,921)	477	(917)
d) Employee benefits expense	4,026	3,838	3,183	13,692
e) Depreciation and amortization expense	1,264	1,280	1,114	4,726
f) Other Expenses	5,615	6,345	5,531	23,261
<b>TOTAL EXPENSES</b>	<b>17,889</b>	<b>16,414</b>	<b>16,393</b>	<b>65,916</b>
<b>05. Profit/(Loss) from Operations before other income, finance costs and exceptional items</b>	<b>4,482</b>	<b>3,666</b>	<b>4,603</b>	<b>16,611</b>
06. Other Income	183	320	152	1,491
<b>07. Profit/(Loss) from ordinary activities before finance Cost and exceptional items</b>	<b>4,665</b>	<b>3,986</b>	<b>4,755</b>	<b>18,102</b>
08. Finance costs	808	937	656	3,168
<b>09. Profit/(Loss) from ordinary activities after finance Costs but before exceptional items</b>	<b>3,857</b>	<b>3,049</b>	<b>4,099</b>	<b>14,934</b>
10. Exceptional Item	-	-	-	1,513
<b>11. Profit/(Loss) from ordinary activities before tax</b>	<b>3,857</b>	<b>3,049</b>	<b>4,099</b>	<b>13,421</b>
12. Current Tax expense	1,017	851	971	3,512
13. Deferred Tax expense /(Reversal)	86	(3,117)	(93)	(3,117)
<b>14. Net Profit/Loss(-) from ordinary activities after tax</b>	<b>2,754</b>	<b>5,315</b>	<b>3,221</b>	<b>13,026</b>
15. Minority Interest	(69)	(129)	(125)	(435)
<b>16. Net Profit/(Loss) for the period</b>	<b>2,823</b>	<b>5,444</b>	<b>3,346</b>	<b>13,461</b>
17. Paid-up Equity Share Capital(each share of Rs.10/-face value)	3,323	3,323	3,307	3,323
18. Reserves excluding revaluation reserves as per Balance Sheet of previous accounting year	-	-	-	81,282
<b>19. Earnings per share</b>				
Basic and diluted EPS before and after extraordinary item (Rs.) – non-annualized	8.50	16.41	10.12	40.64
	8.50	16.41	10.12	40.64
<b>PART II : SELECT INFORMATION</b>				
20. Public Share holding :				
a) Number of Shares	1,53,68,985	1,53,73,985	1,53,73,943	1,53,73,985
b) Percentage of Share holding	46.24	46.26	46.48	46.26
21. Promoters and Promoter Group Shareholding				
a) Pledged/Encumbered – No.of shares	-	-	-	-
b) Non-encumbered–No.of shares	1,78,65,864	1,78,60,864	1,76,99,131	1,78,60,864
Percentage (as a % of the total share holding of promoter and promoter group)	100.00	100.00	100.00	100.00
Percentage (as a % of the total share capital of the company)	53.76	53.74	53.52	53.74

The above un-audited financial results were reviewed by the Audit Committee, and approved by the Board of Directors at a meeting held at Hyderabad, on Wednesday, the 12th August, 2015. There are no exceptional and extraordinary items to be reported for the period under review. The stand alone result are available on the company website [www.natcopharma.co.in](http://www.natcopharma.co.in).

Dated at Hyderabad, this, the 12th day of August, 2015.  
for and on behalf of the Board of Directors,  
NATCO Pharma Limited

*R. Nannapaneni*  
**Rajeev Nannapaneni**  
Vice Chairman & CEO

Status of Investor Complaints as at 30th June, 2015	
Pending as on 01-04-2015	-
Received during the quarter	115
Resolved during the quarter	115
Pending as on 30-06-2015	-



**NATCO PHARMA LIMITED**

**Report of segment wise revenue, Results and Capital Employed (Un-audited) under Clause 41 of the Listing Agreement, for the quarter ended on 30th June, 2015**

Rs. In lakhs

PARTICULARS	THREE MONTHS ENDED			PREVIOUS ACCOUNTING YEAR ENDED (UN-AUDITED)
	30-Jun-15	31-Mar-15	30-Jun-14	31-Mar-15
<b>01. Segment Revenue(Net)</b>				
a) Bulk Chemicals	5,580	7,171	8,527	29,468
b) Formulations	14,146	11,943	8,966	42,524
c) Job Work	221	218	230	830
d) Unallocated	326	504	970	2,502
<b>Total</b>	<b>20,273</b>	<b>19,836</b>	<b>18,693</b>	<b>75,324</b>
Less: Inter-Segment Revenue	868	2,251	545	3,767
<b>Net Sales/Income from Operations</b>	<b>19,405</b>	<b>17,585</b>	<b>18,148</b>	<b>71,557</b>
<b>02. Segment Results: Profit(+)/Loss(-) before tax and interest</b>				
a) Bulk Chemicals	1,134	2,593	3,957	8,043
b) Formulations	5,712	4,159	3,068	17,784
c) Job Work	190	179	183	684
d) Unallocated	243	673	53	1,354
<b>Total</b>	<b>7,279</b>	<b>7,604</b>	<b>7,261</b>	<b>27,865</b>
Less: a) Interest	777	867	636	3,013
b) Other unallocable expenditure	2,344	2,808	2,224	10,766
c) Unallocable Income	(283)	(255)	(88)	(1,355)
<b>Total Profit Before Tax</b>	<b>4,441</b>	<b>4,184</b>	<b>4,489</b>	<b>15,441</b>
<b>03. Capital Employed (Segment Assets- Segment Liabilities)</b>				
a) Bulk Chemicals	46,963	44,091	45,748	44,091
b) Formulations	45,123	44,740	30,176	44,740
c) Job Work	101	227	212	227
d) Unallocated (Others)	(881)	(1,159)	173	(1,159)
<b>Total</b>	<b>91,306</b>	<b>87,899</b>	<b>76,309</b>	<b>87,899</b>

The above un-audited financial results were reviewed by the Audit Committee, Statutory Auditors and approved by the Board of Directors at a meeting held at Hyderabad, on Wednesday, the 12th August, 2015. Figures for the previous period(s) have been re-arranged / re-grouped wherever necessary.

Exceptional item for the year ended 31 March 2015, represents amount paid and accounted against settlement of pending legal dispute Rs.1513/- lakhs. On the basis of management's assessment of its future business plan and the impact thereof on the future taxable income, the management believes that the Company would continue to pay tax on income under the Minimum Alternate Tax (MAT) provisions of the Income Tax Act, 1961 over the next several years. Thus, deferred tax liabilities (net) aggregating to Rs.3103/- lakhs recognized in the earlier years on the timing differences which is expected to be reversed during the MAT period is de-recognized during the quarter ended 31 March 2015 in accordance with the provisions of Accounting Standard 22 – 'Accounting for Taxes on Income'.

Dated at Hyderabad, this, the 12th day of August, 2015.  
for and on behalf of the Board of Directors,  
NATCO Pharma Limited

**Rajeev Nannapaneni**  
**Vice Chairman & CEO**